Replies to post #16805 on Marker Therapeutics Inc (MRKR)

[Rkmatters]

The combo trial is but a month old. It is the first time they are testing in patients with tumors.

The final efficacy results of the prior Phase I trial has yet to be reported. And it is time to disease recurrence as a final endpoint. Beyond that, your post on efficacy results is such poor comparison. Essentially they were treating patients who technically had no tumors but residual cancer cells/disease who were a high likelihood to recur. The patients in their trial were out of treatment options and significant extension will be highly valuable. Based on their Phase I primary endpoint TPIV received FAST TRACK in Ovarian, whereas IMGN did not. To suggest it isn't as good as IMGN is bizarre. It's likely better.

[LloydDC]

Tapimmune corporate presentation notes FRa expressed in 80% NSCLC. I'm not a scientist but AZN ovarian combo trial results may beg the question of what does that combo look like in NSCLC. Also a more recent update on the IMGN FRa targeted ADC

http://investor.immunogen.com/releasedetail.cfm?ReleaseID=1026885

AIDS became a lifelong treatable disease through combo (cocktail) approaches. Cure could be around the corner.

So much research going on
hopefully most cancers are next